Abstract
Breast cancer is one of the most common type of cancers as well as a principal cause of cancer-related deaths in women worldwide. Although research has provided a better understanding and diagnosis of breast cancer, studies in breast cancer therapeutics are still far from satisfactory. Recent research on microRNAs (miRNAs) has implicated these tiny regulatory molecules in progression of breast cancer with the possibility of exploiting them as diagnostic and/or prognostic biomarkers. The loss of tumor suppressor miRNAs or overexpression of oncogenic miRNAs can lead to breast cancer tumorigenesis or metastasis. However, the next step – linking miRNAs to cancer therapeutics – is still under progression. The roles of miRNAs exhibit much potential in breast cancer therapy, but currently need to be further studied and evaluated in order to better understand how to apply laboratory results to clinical medicine. Here we provide an update on our current understanding of miRNAs as molecular targets for diagnosis, prognosis and therapy of breast cancers.
Keywords: microRNAs (miRNAs), breast cancer therapy, diagnostic biomarkers, prognostic biomarkers.
Current Pharmaceutical Design
Title:MicroRNAs in Breast Cancer Therapy
Volume: 20 Issue: 33
Author(s): Joy Tang, Aamir Ahmad and Fazlul H. Sarkar
Affiliation:
Keywords: microRNAs (miRNAs), breast cancer therapy, diagnostic biomarkers, prognostic biomarkers.
Abstract: Breast cancer is one of the most common type of cancers as well as a principal cause of cancer-related deaths in women worldwide. Although research has provided a better understanding and diagnosis of breast cancer, studies in breast cancer therapeutics are still far from satisfactory. Recent research on microRNAs (miRNAs) has implicated these tiny regulatory molecules in progression of breast cancer with the possibility of exploiting them as diagnostic and/or prognostic biomarkers. The loss of tumor suppressor miRNAs or overexpression of oncogenic miRNAs can lead to breast cancer tumorigenesis or metastasis. However, the next step – linking miRNAs to cancer therapeutics – is still under progression. The roles of miRNAs exhibit much potential in breast cancer therapy, but currently need to be further studied and evaluated in order to better understand how to apply laboratory results to clinical medicine. Here we provide an update on our current understanding of miRNAs as molecular targets for diagnosis, prognosis and therapy of breast cancers.
Export Options
About this article
Cite this article as:
Tang Joy, Ahmad Aamir and Sarkar H. Fazlul, MicroRNAs in Breast Cancer Therapy, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128205239
DOI https://dx.doi.org/10.2174/1381612820666140128205239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Chemical Biology Glucuronides in Anti-Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Defensive Role of Plant-Derived Secondary Metabolites: Indole and Its’ Derivatives
Current Biotechnology Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets Functional Food: Product Development and Health Benefits
Recent Patents on Engineering Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-methanones as Novel Inflammation Medication
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Translating Mismatch Repair Mechanism into Cancer Care
Current Drug Targets Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats
Drug Metabolism Letters MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology